ALEMBICLTDstockAlembic Ltd
₹91
▲+2.03%
Open
₹89
High
₹91.59
Low
₹88.97
Volume
364.7K
Price chart
Daily close · downsampled 5-year history
2021-06-21 · ₹130.952026-06-18 · ₹93.95
Instrument details
- MB Code
- MBEQU2512
- Type
- stock
- ISIN
- INE426A01027
- BSE
- 506235
- Industry
- Realty
Latest earnings
Q4FY26 declared
- Quarter
- Mar 2026
- Revenue
- 60.04 Cr
- Net profit
- 9.61 Cr
- EPS
- 2.61
- YoY revenue
- -0.38%
Price returns
Historical performance
- 1 day
- +3.39%
- 1 month
- +4.44%
- 3 months
- +17.70%
- 1 year
- -17.80%
- 3 years
- +28.31%
- 5 years
- -29.78%
Technicals
Indicator consensus
Bullish
34
Neutral
2
Bearish
10
RSI 81.81(Bearish)
Company documents
Annual reports, concalls, presentations
Corporate announcements
156Corporate timeline
Price chart events · 1 year
Dividend
2025-08-05
{"amount":2.4}
News
2025-11-04
{"description":"Alembic Pharmaceuticals reported a 21% rise in Q2 profit to ₹185 crore, driven by strong US generics and API growth. Revenue increased 16% to ₹1,910 crore. Shares jumped over 7% following the earnings announcement on November 4, 2025.","url":"https://www.cnbctv18.com/market/earnings/alembic-pharma-q2-results-profit-up-21-pc-shares-jump-7-pc-on-strong-us-api-growth-ws-l-19741161.htm","sentiment":"Positive","domain":"CNBCTV18"}
News
2025-08-05
{"description":"Alembic Pharma's profit for the June quarter rose 15% due to a 13% year-on-year increase in US generics sales.","url":"https://www.moneycontrol.com/news/business/earnings/alembic-pharma-s-june-quarter-profit-grows-25-percent-strong-us-generics-sales-13392556.html","sentiment":"Positive","domain":"Moneycontrol"}
News
2025-06-30
{"description":"Alembic Pharmaceuticals' shares rose over 12% following USFDA approval for its generic Doxorubicin, a cancer treatment.","url":"https://www.livemint.com/market/stock-market-news/alembic-pharma-surges-over-12-on-usfda-approval-for-cancer-drug-11751258142994.html","sentiment":"Positive","domain":"Mint"}